Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial

BACKGROUND: Surgical resection is a mainstay to treat hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in east Asia. However, the postoperative recurrence rate is high. It is necessary to explore neo-adjuvant therapy to increase the surgical resection rate and improve overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guangxin, Shu, Bin, Zheng, Zhuozhao, Yin, Hongfang, Zhang, Chen, Xiao, Ying, Yang, Yanmei, Yan, Zhe, Zhang, Xiaofei, Yang, Shizhong, Li, Gong, Dong, Jiahong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730694/
https://www.ncbi.nlm.nih.gov/pubmed/36505833
http://dx.doi.org/10.3389/fonc.2022.1051916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730694/
https://www.ncbi.nlm.nih.gov/pubmed/36505833
http://dx.doi.org/10.3389/fonc.2022.1051916

Ejemplares similares